Is Eris Lifesciences Limited’s (NSE:ERIS) ROE Of 33.29% Sustainable?

This analysis is intended to introduce important early concepts to people who are starting to invest and want to learn about Return on Equity using a real-life example.

With an ROE of 33.29%, Eris Lifesciences Limited (NSE:ERIS) outpaced its own industry which delivered a less exciting 10.69% over the past year. Though, the impressiveness of ERIS’s ROE is contingent on whether this industry-beating level can be sustained. This can be measured by looking at the company’s financial leverage. With more debt, ERIS can invest even more and earn more money, thus pushing up its returns. However, ROE only measures returns against equity, not debt. This can be distorted, so let’s take a look at it further.

View our latest analysis for Eris Lifesciences

Breaking down Return on Equity

Return on Equity (ROE) is a measure of Eris Lifesciences’s profit relative to its shareholders’ equity. It essentially shows how much the company can generate in earnings given the amount of equity it has raised. If investors diversify their portfolio by industry, they may want to maximise their return in the Pharmaceuticals sector by investing in the highest returning stock. However, this can be misleading as each firm has different costs of equity and debt levels i.e. the more debt Eris Lifesciences has, the higher ROE is pumped up in the short term, at the expense of long term interest payment burden.

Return on Equity = Net Profit ÷ Shareholders Equity

ROE is measured against cost of equity in order to determine the efficiency of Eris Lifesciences’s equity capital deployed. Its cost of equity is 13.55%. Since Eris Lifesciences’s return covers its cost in excess of 19.75%, its use of equity capital is efficient and likely to be sustainable. Simply put, Eris Lifesciences pays less for its capital than what it generates in return. ROE can be dissected into three distinct ratios: net profit margin, asset turnover, and financial leverage. This is called the Dupont Formula:

Dupont Formula

ROE = profit margin × asset turnover × financial leverage

ROE = (annual net profit ÷ sales) × (sales ÷ assets) × (assets ÷ shareholders’ equity)

ROE = annual net profit ÷ shareholders’ equity

NSEI:ERIS Last Perf July 17th 18
NSEI:ERIS Last Perf July 17th 18

The first component is profit margin, which measures how much of sales is retained after the company pays for all its expenses. The other component, asset turnover, illustrates how much revenue Eris Lifesciences can make from its asset base. Finally, financial leverage will be our main focus today. It shows how much of assets are funded by equity and can show how sustainable the company’s capital structure is. We can assess whether Eris Lifesciences is fuelling ROE by excessively raising debt. Ideally, Eris Lifesciences should have a balanced capital structure, which we can check by looking at the historic debt-to-equity ratio of the company. The most recent ratio is 30.95%, which is sensible and indicates Eris Lifesciences has not taken on too much leverage. Thus, we can conclude its above-average ROE is generated from its capacity to increase profit without a large debt burden.

NSEI:ERIS Historical Debt July 17th 18
NSEI:ERIS Historical Debt July 17th 18

Next Steps:

ROE is a simple yet informative ratio, illustrating the various components that each measure the quality of the overall stock. Eris Lifesciences’s ROE is impressive relative to the industry average and also covers its cost of equity. ROE is not likely to be inflated by excessive debt funding, giving shareholders more conviction in the sustainability of high returns. ROE is a helpful signal, but it is definitely not sufficient on its own to make an investment decision.

For Eris Lifesciences, there are three essential factors you should further research:

  1. Financial Health: Does it have a healthy balance sheet? Take a look at our free balance sheet analysis with six simple checks on key factors like leverage and risk.
  2. Valuation: What is Eris Lifesciences worth today? Is the stock undervalued, even when its growth outlook is factored into its intrinsic value? The intrinsic value infographic in our free research report helps visualize whether Eris Lifesciences is currently mispriced by the market.
  3. Other High-Growth Alternatives : Are there other high-growth stocks you could be holding instead of Eris Lifesciences? Explore our interactive list of stocks with large growth potential to get an idea of what else is out there you may be missing!